Literature DB >> 1445977

Persistence of serum antibodies to Borrelia burgdorferi in patients treated for Lyme disease.

H M Feder1, M A Gerber, S W Luger, R W Ryan.   

Abstract

To determine if antibodies to Borrelia burgdorferi persist after antibiotic treatment, we recalled 32 patients with Lyme disease from a primary care practice a mean of 16 months after treatment and analyzed initial and follow-up serum samples by ELISA and immunoblot assays. Of the eight patients whose initial serum specimens were positive for IgM antibody by ELISA, three had positive titers of IgM antibody at follow-up; of the 23 patients whose initial serum specimens were positive for IgG antibody by ELISA, 19 had positive titers of IgG at follow-up. Of the five patients whose initial serum specimens were positive for IgM antibody by immunoblot, two had positive titers of IgM antibody at follow-up; of the 30 patients whose initial serum specimens were positive for IgG antibody by immunoblot, 29 had positive titers of IgG antibody at follow-up. The bands on the IgG immunoblot remained remarkably constant during the period from analysis of the initial specimen to that of the follow-up specimen. Nine of the 32 patients had persistent or recurrent symptoms, and ELISA and immunoblot were not helpful for identifying these nine patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1445977     DOI: 10.1093/clind/15.5.788

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  27 in total

Review 1.  Overdiagnosis and overtreatment of Lyme neuroborreliosis are preventable.

Authors:  A Prasad; D Sankar
Journal:  Postgrad Med J       Date:  1999-11       Impact factor: 2.401

2.  Evaluation of the recombinant VlsE-based liaison chemiluminescence immunoassay for detection of Borrelia burgdorferi and diagnosis of Lyme disease.

Authors:  Thomas B Ledue; Marilyn F Collins; John Young; Martin E Schriefer
Journal:  Clin Vaccine Immunol       Date:  2008-10-22

3.  Temporal study of immunoglobin M seroreactivity to Borrelia burgdorferi in patients treated for Lyme borreliosis.

Authors:  E Hilton; A Tramontano; J DeVoti; S K Sood
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

4.  Detection of anti-Borrelia burgdorferi antibody responses with the borreliacidal antibody test, indirect fluorescent-antibody assay performed by flow cytometry, and western immunoblotting.

Authors:  J R Creson; L C Lim; N J Glowacki; S M Callister; R F Schell
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

5.  Lessons Learned from a Rhode Island Academic Out-Patient Lyme and Tick-Borne Disease Clinic.

Authors:  Meghan L McCarthy; Rebecca Reece; Sara E Vargas; Jennie Johnson; Jennifer Adelson-Mitty; Timothy Flanigan
Journal:  R I Med J (2013)       Date:  2020-12-01

6.  Evaluation of Modified 2-Tiered Serodiagnostic Testing Algorithms for Early Lyme Disease.

Authors:  John A Branda; Klemen Strle; Lise E Nigrovic; Paul M Lantos; Timothy J Lepore; Nitin S Damle; Mary Jane Ferraro; Allen C Steere
Journal:  Clin Infect Dis       Date:  2017-04-15       Impact factor: 9.079

7.  Impact of strain heterogeneity on Lyme disease serology in Europe: comparison of enzyme-linked immunosorbent assays using different species of Borrelia burgdorferi sensu lato.

Authors:  U Hauser; H Krahl; H Peters; V Fingerle; B Wilske
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

8.  Lyme borreliosis--an overdiagnosed disease?

Authors:  B Svenungsson; G Lindh
Journal:  Infection       Date:  1997 May-Jun       Impact factor: 3.553

Review 9.  Coinfections acquired from ixodes ticks.

Authors:  Stephen J Swanson; David Neitzel; Kurt D Reed; Edward A Belongia
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

10.  Temperature-related differential expression of antigens in the Lyme disease spirochete, Borrelia burgdorferi.

Authors:  B Stevenson; T G Schwan; P A Rosa
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.